Bruce Brown
Research Subjects
Bruce Brown has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aliyah H. Remoroza1 shared publication
- Gabriela Mansano Do Nascimento
Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
1 shared publication - Hannah Ambrose1 shared publication
- Jaikin E. Harrell
Department of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA 70112, USA
1 shared publication - Ligia A. Pinto
Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA
1 shared publication - Matthew Drew
National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc
1 shared publication
Latest Publications
- Open Access
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Analytical Evaluation of SARS CoV 2 Spike Protein Stability across Routine Aliquoting and Freezing Methods
Serological assays are essential for infectious disease surveillance and vaccine evaluation because they detect antibody responses that persist beyond the period of active viral replication. The reliability of these assays, however, depends heavily on the structural and functional stability of the antigens used. Recombinant proteins—such as the SARS‑CoV‑2 Spike—are vulnerable to degradation from suboptimal handling, storage, and repeated freeze–thaw cycles, which can compromise assay performance. To address this concern, we systematically assessed the impact of three commonly used aliquoting and freezing approaches on the long‑term stability of a recombinant SARS‑CoV‑2 Spike protein: (1) aliquoting on wet ice followed by storage at −80 °C, (2) aliquoting on dry ice followed by storage at −80 °C, and (3) aliquoting on dry ice followed by snap‑freezing in a methanol–dry ice bath. Aliquots from two manufacturing lots were evaluated over six months using multiple quality metrics, including purity, structural integrity [Analytical Size Exclusion Chromatography (AnSEC) and Thermal Shift Assay (TSA)], and functional performance in a validated IgG ELISA. Across all conditions and time points, antigen purity remained within the ideal A260/A280 range (0.6–0.8), with minimal nucleic acid contamination. ELISA performance demonstrated consistently low background and high sensitivity, specificity, and precision. Structural analyses confirmed stable protein size and conformation (AnSEC elution peaks within ±1.0 mL of baseline) and unchanged thermal stability (Tm within ±2.0 °C). These findings indicate that all tested methodologies effectively preserved antigen integrity under controlled laboratory conditions, providing a foundation for standardized SOPs while acknowledging that real‑world variability may influence outcomes.
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAnalytical Evaluation of SARS CoV 2 Spike Protein Stability across Routine Aliquoting and Freezing Methods
Serological assays are essential for infectious disease surveillance and vaccine evaluation because they detect antibody responses that persist beyond the period of active viral replication. The reliability of these assays, however, depends heavily on the structural and functional stability of the antigens used. Recombinant proteins—such as the SARS‑CoV‑2 Spike—are vulnerable to degradation from suboptimal handling, storage, and repeated freeze–thaw cycles, which can compromise assay performance. To address this concern, we systematically assessed the impact of three commonly used aliquoting and freezing approaches on the long‑term stability of a recombinant SARS‑CoV‑2 Spike protein: (1) aliquoting on wet ice followed by storage at −80 °C, (2) aliquoting on dry ice followed by storage at −80 °C, and (3) aliquoting on dry ice followed by snap‑freezing in a methanol–dry ice bath. Aliquots from two manufacturing lots were evaluated over six months using multiple quality metrics, including purity, structural integrity [Analytical Size Exclusion Chromatography (AnSEC) and Thermal Shift Assay (TSA)], and functional performance in a validated IgG ELISA. Across all conditions and time points, antigen purity remained within the ideal A260/A280 range (0.6–0.8), with minimal nucleic acid contamination. ELISA performance demonstrated consistently low background and high sensitivity, specificity, and precision. Structural analyses confirmed stable protein size and conformation (AnSEC elution peaks within ±1.0 mL of baseline) and unchanged thermal stability (Tm within ±2.0 °C). These findings indicate that all tested methodologies effectively preserved antigen integrity under controlled laboratory conditions, providing a foundation for standardized SOPs while acknowledging that real‑world variability may influence outcomes.